Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CASC

(CASC) (CASC) Stock Price, News & Analysis

(CASC) logo

About (CASC) Stock (NASDAQ:CASC)

Advanced Chart

Key Stats

Today's Range
$10.02
$10.02
50-Day Range
N/A
52-Week Range
$3.18
$10.21
Volume
N/A
Average Volume
1.09 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive CASC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (CASC) and its competitors with MarketBeat's FREE daily newsletter.

CASC Stock News Headlines

The Social Security Changes No One’s Talking About
While most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.
See More Headlines

CASC Stock Analysis - Frequently Asked Questions

(CASC) (NASDAQ:CASC) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that (CASC) investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and NIC (EGOV).

Company Calendar

Last Earnings
11/08/2017
Today
6/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CASC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:CASC) was last updated on 6/3/2025 by MarketBeat.com Staff
From Our Partners